Results 161 to 170 of about 291,154 (262)

A set of serum proteomic biomarkers differentiates celiac children from age and human leukocyte antigen-matched healthy controls. [PDF]

J Pediatr Gastroenterol Nutr
Mandile R, di Tolla MF, Carpinelli M, Samsom JN, De Cegli R, Barone MV, Troncone R, Formisano P, Greco L, Auricchio R.   +9 more
europepmc   +1 more source

Autoreactivity Versus Autoimmunity: Characteristics of Autoantigen‐Specific CD4 T Cells in Rheumatoid Arthritis and Health

Arthritis &Rheumatology, EarlyView.
Objective CD4 T cells specific for citrullinated (cit) peptides are key players in rheumatoid arthritis (RA) immunopathogenesis. Characterizing these cells and identifying features of healthy and RA‐associated autoreactivity will provide valuable insight into disease mechanisms and form the basis of immune state biomarkers to facilitate the next ...
James A. Stanway, Daniel Peters, Helen Waller, Jeremy Lakey, Henrique De Paula Lemos, Kristian Williams, Abbie Degnan, Julie Diboll, Abdul Mannan Baru, David Tough, Arthur G. Pratt, Catharien M.U. Hilkens, Amy E. Anderson, John D. Isaacs   +13 more
wiley   +1 more source

Correction: Effect of preexisting human leukocyte antigen donor-specific antibodies especially human leukocyte antigen-DQ on kidney transplant outcome

Frontiers in Nephrology
Sonia Mehrotra, Raj Kumar Sharma, Rakesh Kapoor, Rajesh Kumar Jaiswal, Rohit Kapoor   +4 more
doaj   +1 more source

Epigenetic analyses suggest different pathways during pregnancy for development of type 1 diabetes in children with high versus low-neutral human leukocyte antigen-risk. [PDF]

J Intern Med
Alipoor SD, Ahrens A, Åkesson J, Hillerton T, Gustafsson M, Lerm M, Ludvigsson J.   +6 more
europepmc   +1 more source

Targeting Amastigote and Trypomastigote Phases: Multi‐Epitope Vaccine Strategy Against Trypanosoma cruzi

Biotechnology and Applied Biochemistry, EarlyView.
ABSTRACT Effective vaccines against Trypanosoma cruzi, the causative agent of Chagas disease, are urgently needed. Here, we report the design and in silico validation of a novel multiepitope vaccine construct targeting the key surface proteins ASP‐2 and gp82. Using a comprehensive immunoinformatics pipeline, we identified and selected 38 potent T‐cell (
Maria Karolaynne da Silva, Caio Patrício de Souza Sena, Davi Serradella Vieira, Magdi E. A. Zaki, Leow Chiuan Yee, Shahina Akter, Umberto Laino Fulco, Jonas Ivan Nobre Oliveira, João Firmino Rodrigues‐Neto   +8 more
wiley   +1 more source

The Impact of Killer Cell Immunoglobulin-Like Receptors and Human Leukocyte Antigen-E, Human Leukocyte Antigen-G Polymorphisms on Innate Immunity and COVID-19 Severity. [PDF]

J Immunol Res
Kekik C, Temurhan S, Ogret Y, Zanjani BN, Kıvanc D, Savran Oguz F, Kose M, Oktelik FB, Deniz G.   +8 more
europepmc   +1 more source

Adverse immunostimulation in early phase clinical trials: Key findings and recommendations based on the investigator's clinical experience

British Journal of Clinical Pharmacology, EarlyView.
Problem setting The emergence of therapeutic proteins has coincided with an increase of acute adverse immunostimulation (AIS). AIS has occured in clinical trials despite compliance with regulatory guidelines on preclinical evaluation and its incidence is anticipated to increase even further.
Juliette A. van den Noort, Marella C. E. van Ruissen, Lisanne C. A. Smidt, Naomi B. Klarenbeek, Philip H. K. Kremer, Manon A. A. Jansen, Jacobus Burggraaf, Joop M. A. van Gerven, Matthijs Moerland   +8 more
wiley   +1 more source

Assessment of Donor-Specific Human Leukocyte Antigen Antibodies Following Pediatric Liver Transplantation: Predictors, Protectors, and Clinical Relevance. [PDF]

Clin Transplant
Kanaan E, Ohlsson S, Kathemann S, Prusinskas B, Tsaka S, Heinemann FM, Heinold A, Schulze M, Pape L, Lainka E.   +9 more
europepmc   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source